SCHEMBL17353047

SCHEMBL17353047

Fc1cc2c(c(C3=NCCCC3)c1)OCCO2

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 11/20 0.43
CHRNA3 P32297 11/20 0.43
CHRNA7 P36544 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15017037 0.95 CHRNB4 (0.38) CHRNB4CHRNA3
SCHEMBL16309079 0.71 CHEK2 (0.38) CHRNB4CHRNA3
SCHEMBL17353143 0.68 CHRNB4 (0.56) CHRNB4CHRNA3CHRNA7
SCHEMBL15039735 0.63 MEN1 (0.41)
SCHEMBL15046893 0.63 HDAC4 (0.39)
SCHEMBL419983 0.63 PARP1 (0.36)
SCHEMBL13534196 0.63 HPGD (0.33)
SCHEMBL29868877 0.63 PARP1 (0.36)
SCHEMBL1137474 0.63 KDM4E (0.35)
SCHEMBL29420191 0.63 CHRNB4 (0.49) CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9782391-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-10-10 US disclosed
US-9782391-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-10-10 US disclosed
US-9782391-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-10-10 US disclosed
EP-3157921-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN Dr. Reddy's Laboratories Ltd. (IN) 2017-04-26 EP disclosed
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-29 US disclosed
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-29 US disclosed
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-29 US disclosed
US-9394305-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2016-07-19 US disclosed
US-9394305-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2016-07-19 US disclosed
US-9394305-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2016-07-19 US disclosed
WO-2015200341-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-30 WO disclosed
WO-2015200341-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-30 WO disclosed
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-24 US disclosed
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-24 US disclosed
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS NTRK1, NTRK3, MUSK CHRNB4 870/4885CHRNA3 439/4885CHRNA7 482/4885
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS NTRK1, NTRK3, MUSK CHRNB4 870/4885CHRNA3 439/4885CHRNA7 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.